FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207050332> ?p ?o ?g. }

• W4207050332 endingPage "1909" @default.
• W4207050332 startingPage "1909" @default.
• W4207050332 abstract "Abstract Background:Introducing tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukemia (CML) has changed the prognosis of this disease from an incurable malignancy to a manageable chronic condition. The need for life-long treatment with TKIs however, requires detailed knowledge of factors that could affect therapy efficacy and toxicity. TKIs are generally well tolerated, nevertheless they may be associated with the so called off-target effects causing specific adverse events (AEs). It has been shown that some co-morbidities may predispose towards developing certain TKIs' off-target AEs, which includes cardiovascular complications or pleural effusion. Furthermore, TKIs are metabolized by the CYP3A4 isoenzyme and have been reported to be substrates of ABCB1 (MDR1) and ABCG2 (BCRP) transporters. Drug interactions should therefore be considered when administering inhibitors or inducers of CYP3A4, ABCB1 and ABCG2 in combination with TKIs. Objective:The aim of this study was a retrospective assessment of the prevalence of both comorbid conditions and use of concomitant medications in a large cohort of newly diagnosed CML patients within a real-world setting. Patients and methods:Data from medical records were retrospectively analyzed on newly diagnosed adult CML patients referred to nine Polish hematological tertiary care centers. Inclusion criteria were as follows: 1) age ≥ 18 years; 2) diagnosis of chronic phase CML between January 1st 2005 and December 31st 2014. Results:Study subjects were 470 consecutive patients diagnosed with CML as per above. Patients' median age was 53.0 years (range 18.0 - 88.9 years). Two hundred sixty-one patients (55.5%) were found to have at least one comorbid condition at CML diagnosis and 268 (57.0 %) received at least one concomitant medication. The median number of concomitant therapies was one (range 0-12). In the analyzed patients cohort the most frequent comorbidities that are of importance regarding the risk of TKI' off target AEs included: hypertension (31%), hypercholesterolemia (11%), ischemic heart disease (10%), diabetes (9%), cardiac insufficiency (5%), history of myocardial infarction (4.5%) significant pulmonary diseases including bronchial asthma, COPD or sarcoidosis (4%) and ischemic stroke (2%). Moreover, 55 patients (11.6%) were cigarette smokers. The median body mass index (BMI) was 25, where 134/392 patients (34%) were qualified as being overweight and 86/392 patients (22%) were obese. Conclusions : Our analysis shows that more than 50% of newly diagnosed CML patients suffer comorbid conditions, and take concomitant medication at the time of CML diagnosis. Because the presence of certain comorbidities increases the risk of TKIs' off-target AEs, it is vital to assess and take into account these co-morbidities when selecting TKI for individual CML patients. Furthermore, potential pharmacokinetic interactions between specific TKIs and concomitant medications, as well as their overlapping toxicities have to be also considered. Disclosures Gora-Tybor: Novartis: Consultancy, Honoraria, Speakers Bureau; Incyte: Consultancy, Honoraria; BMS: Consultancy, Honoraria, Speakers Bureau; Pfizer: Consultancy, Honoraria. Sacha:BMS: Consultancy, Honoraria, Speakers Bureau; Pfizer: Consultancy, Honoraria, Speakers Bureau; Incyte: Consultancy, Honoraria, Speakers Bureau; Adamed: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Speakers Bureau. Grzybowska-Izydorczyk:BMS: Honoraria; Novartis: Honoraria. Seferynska:Novartis: Consultancy, Honoraria. Lewandowski:Novartis: Consultancy, Honoraria, Speakers Bureau; Incyte: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; BMS: Consultancy, Honoraria, Speakers Bureau. Warzocha:Novartis: Consultancy, Honoraria; BMS: Consultancy, Honoraria. Jamroziak:Novartis: Consultancy, Honoraria; BMS: Consultancy, Honoraria." @default.
• W4207050332 created "2022-01-26" @default.
• W4207050332 creator A5008828017 @default.
• W4207050332 creator A5019711205 @default.
• W4207050332 creator A5026062357 @default.
• W4207050332 creator A5029712912 @default.
• W4207050332 creator A5034883916 @default.
• W4207050332 creator A5039221511 @default.
• W4207050332 creator A5039661217 @default.
• W4207050332 creator A5043771554 @default.
• W4207050332 creator A5045616098 @default.
• W4207050332 creator A5056325517 @default.
• W4207050332 creator A5059212245 @default.
• W4207050332 creator A5062641058 @default.
• W4207050332 creator A5064484491 @default.
• W4207050332 creator A5069689331 @default.
• W4207050332 creator A5090451317 @default.
• W4207050332 date "2016-12-02" @default.
• W4207050332 modified "2023-10-18" @default.
• W4207050332 title "Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 470 Patients from the Polish Adult Leukemia Group (PALG) Registry" @default.
• W4207050332 doi "https://doi.org/10.1182/blood.v128.22.1909.1909" @default.
• W4207050332 hasPublicationYear "2016" @default.
• W4207050332 type Work @default.
• W4207050332 citedByCount "1" @default.
• W4207050332 countsByYear W42070503322023 @default.
• W4207050332 crossrefType "journal-article" @default.
• W4207050332 hasAuthorship W4207050332A5008828017 @default.
• W4207050332 hasAuthorship W4207050332A5019711205 @default.
• W4207050332 hasAuthorship W4207050332A5026062357 @default.
• W4207050332 hasAuthorship W4207050332A5029712912 @default.
• W4207050332 hasAuthorship W4207050332A5034883916 @default.
• W4207050332 hasAuthorship W4207050332A5039221511 @default.
• W4207050332 hasAuthorship W4207050332A5039661217 @default.
• W4207050332 hasAuthorship W4207050332A5043771554 @default.
• W4207050332 hasAuthorship W4207050332A5045616098 @default.
• W4207050332 hasAuthorship W4207050332A5056325517 @default.
• W4207050332 hasAuthorship W4207050332A5059212245 @default.
• W4207050332 hasAuthorship W4207050332A5062641058 @default.
• W4207050332 hasAuthorship W4207050332A5064484491 @default.
• W4207050332 hasAuthorship W4207050332A5069689331 @default.
• W4207050332 hasAuthorship W4207050332A5090451317 @default.
• W4207050332 hasConcept C126322002 @default.
• W4207050332 hasConcept C167135981 @default.
• W4207050332 hasConcept C187212893 @default.
• W4207050332 hasConcept C197934379 @default.
• W4207050332 hasConcept C2777583451 @default.
• W4207050332 hasConcept C2778715236 @default.
• W4207050332 hasConcept C2778729363 @default.
• W4207050332 hasConcept C2779159551 @default.
• W4207050332 hasConcept C2779384505 @default.
• W4207050332 hasConcept C71924100 @default.
• W4207050332 hasConceptScore W4207050332C126322002 @default.
• W4207050332 hasConceptScore W4207050332C167135981 @default.
• W4207050332 hasConceptScore W4207050332C187212893 @default.
• W4207050332 hasConceptScore W4207050332C197934379 @default.
• W4207050332 hasConceptScore W4207050332C2777583451 @default.
• W4207050332 hasConceptScore W4207050332C2778715236 @default.
• W4207050332 hasConceptScore W4207050332C2778729363 @default.
• W4207050332 hasConceptScore W4207050332C2779159551 @default.
• W4207050332 hasConceptScore W4207050332C2779384505 @default.
• W4207050332 hasConceptScore W4207050332C71924100 @default.
• W4207050332 hasIssue "22" @default.
• W4207050332 hasLocation W42070503321 @default.
• W4207050332 hasOpenAccess W4207050332 @default.
• W4207050332 hasPrimaryLocation W42070503321 @default.
• W4207050332 hasRelatedWork W1915791887 @default.
• W4207050332 hasRelatedWork W2057257241 @default.
• W4207050332 hasRelatedWork W2157069029 @default.
• W4207050332 hasRelatedWork W2158958466 @default.
• W4207050332 hasRelatedWork W2278657325 @default.
• W4207050332 hasRelatedWork W2392515536 @default.
• W4207050332 hasRelatedWork W3030758756 @default.
• W4207050332 hasRelatedWork W3134475002 @default.
• W4207050332 hasRelatedWork W3194624016 @default.
• W4207050332 hasRelatedWork W2718479979 @default.
• W4207050332 hasVolume "128" @default.
• W4207050332 isParatext "false" @default.
• W4207050332 isRetracted "false" @default.
• W4207050332 workType "article" @default.